Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of brain-derived neurotrophic factor on activity-regulated cytoskeleton-associated protein gene expression in primary frontal cortical neurons. Comparison with NMDA and AMPA

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{40626225eca34a0e95553ff0ad2b261d,
title = "Effect of brain-derived neurotrophic factor on activity-regulated cytoskeleton-associated protein gene expression in primary frontal cortical neurons. Comparison with NMDA and AMPA",
abstract = "The effect of brain-derived neurotrophic factor (BDNF) on activity-regulated cytoskeleton-associated protein (Arc) mRNA levels in primary neuronal cultures of rat frontal cortex was characterized pharmacologically and compared to the effect on expression of c-fos, bdnf, neuritin, cox-2 as examples of other immediate early genes. BDNF induced a very strong increase (around 100 fold) in Arc mRNA and the maximal effect seen at 25 ng/ml. The effect was dose-dependent with EC50 around 1.6 ng/ml. The time profile revealed a significant effect after 25 min. BDNF also increased levels of c-Fos, neuritin and BDNF mRNA, but not COX-2 mRNA. The pharmacological profile of NMDA and AMPA-induced arc gene expression in frontal cortical neurons was compared to BDNF. NMDA and AMPA increased Arc mRNA but their maximal effect did not exceed 20-fold. The effect of AMPA was completely blocked by the NMDA receptor antagonist MK-801. Further, the relative amount of Arc mRNA compared to c-Fos mRNA was higher for BDNF, equal for NMDA and lower for AMPA. These results demonstrate BDNF to be a highly potent and efficient inducer of arc gene expression in vitro, emphasizing the role of this growth factor in synaptic plasticity in the frontal cortex.",
keywords = "Animals, Brain-Derived Neurotrophic Factor, Cytoskeletal Proteins, Dose-Response Relationship, Drug, Female, Frontal Lobe, Gene Expression Regulation, Humans, N-Methylaspartate, Nerve Tissue Proteins, Neurons, Pregnancy, Proto-Oncogene Proteins c-fos, RNA, Messenger, Rats, Rats, Sprague-Dawley, Receptors, AMPA, Receptors, N-Methyl-D-Aspartate, Time, alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid",
author = "Mona El-Sayed and Jacob Hofman-Bang and Mikkelsen, {Jens D}",
note = "Copyright {\textcopyright} 2011. Published by Elsevier B.V.",
year = "2011",
doi = "10.1016/j.ejphar.2011.03.055",
language = "English",
volume = "660",
pages = "351--7",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer",
number = "2-3",

}

RIS

TY - JOUR

T1 - Effect of brain-derived neurotrophic factor on activity-regulated cytoskeleton-associated protein gene expression in primary frontal cortical neurons. Comparison with NMDA and AMPA

AU - El-Sayed, Mona

AU - Hofman-Bang, Jacob

AU - Mikkelsen, Jens D

N1 - Copyright © 2011. Published by Elsevier B.V.

PY - 2011

Y1 - 2011

N2 - The effect of brain-derived neurotrophic factor (BDNF) on activity-regulated cytoskeleton-associated protein (Arc) mRNA levels in primary neuronal cultures of rat frontal cortex was characterized pharmacologically and compared to the effect on expression of c-fos, bdnf, neuritin, cox-2 as examples of other immediate early genes. BDNF induced a very strong increase (around 100 fold) in Arc mRNA and the maximal effect seen at 25 ng/ml. The effect was dose-dependent with EC50 around 1.6 ng/ml. The time profile revealed a significant effect after 25 min. BDNF also increased levels of c-Fos, neuritin and BDNF mRNA, but not COX-2 mRNA. The pharmacological profile of NMDA and AMPA-induced arc gene expression in frontal cortical neurons was compared to BDNF. NMDA and AMPA increased Arc mRNA but their maximal effect did not exceed 20-fold. The effect of AMPA was completely blocked by the NMDA receptor antagonist MK-801. Further, the relative amount of Arc mRNA compared to c-Fos mRNA was higher for BDNF, equal for NMDA and lower for AMPA. These results demonstrate BDNF to be a highly potent and efficient inducer of arc gene expression in vitro, emphasizing the role of this growth factor in synaptic plasticity in the frontal cortex.

AB - The effect of brain-derived neurotrophic factor (BDNF) on activity-regulated cytoskeleton-associated protein (Arc) mRNA levels in primary neuronal cultures of rat frontal cortex was characterized pharmacologically and compared to the effect on expression of c-fos, bdnf, neuritin, cox-2 as examples of other immediate early genes. BDNF induced a very strong increase (around 100 fold) in Arc mRNA and the maximal effect seen at 25 ng/ml. The effect was dose-dependent with EC50 around 1.6 ng/ml. The time profile revealed a significant effect after 25 min. BDNF also increased levels of c-Fos, neuritin and BDNF mRNA, but not COX-2 mRNA. The pharmacological profile of NMDA and AMPA-induced arc gene expression in frontal cortical neurons was compared to BDNF. NMDA and AMPA increased Arc mRNA but their maximal effect did not exceed 20-fold. The effect of AMPA was completely blocked by the NMDA receptor antagonist MK-801. Further, the relative amount of Arc mRNA compared to c-Fos mRNA was higher for BDNF, equal for NMDA and lower for AMPA. These results demonstrate BDNF to be a highly potent and efficient inducer of arc gene expression in vitro, emphasizing the role of this growth factor in synaptic plasticity in the frontal cortex.

KW - Animals

KW - Brain-Derived Neurotrophic Factor

KW - Cytoskeletal Proteins

KW - Dose-Response Relationship, Drug

KW - Female

KW - Frontal Lobe

KW - Gene Expression Regulation

KW - Humans

KW - N-Methylaspartate

KW - Nerve Tissue Proteins

KW - Neurons

KW - Pregnancy

KW - Proto-Oncogene Proteins c-fos

KW - RNA, Messenger

KW - Rats

KW - Rats, Sprague-Dawley

KW - Receptors, AMPA

KW - Receptors, N-Methyl-D-Aspartate

KW - Time

KW - alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid

U2 - 10.1016/j.ejphar.2011.03.055

DO - 10.1016/j.ejphar.2011.03.055

M3 - Journal article

C2 - 21515256

VL - 660

SP - 351

EP - 357

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 2-3

ER -

ID: 33171034